1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

FTC Homeopathic Meeting Features Tort Attorney, Commissioner Critical Of Enforcement

 
• By Malcolm Spicer

The event agenda includes eight industry executives, researchers, attorneys and FDA officials who made presentations or were agency panel members at FDA’s public hearing in April. Commissioner Maureen Ohlhausen, who has advocated allowing firms regulatory room to advertise, speaks to open the meeting.

The agenda for the Federal Trade Commission’s Sept. 21 workshop on advertising for OTC homeopathics bears a resemblance to FDA’s meeting on regulating the products earlier in 2015, including a plaintiffs’ attorney who was scheduled but did not present at the FDA event.

The FTC event in Washington is scheduled to open at 9:30 a.m. with remarks by Commissioner Maureen Ohlhausen, who has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By Sue Sutter

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

US FDA Chief Counsel Position Awaits HHS General Counsel Confirmation

 
• By Sue Sutter

Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.